Vagus Nerve Stimulation (CPB 0191, reviewed 2026-03-31)
Aetna's Vagus Nerve Stimulation policy (CPB 0191, reviewed March 31, 2026) considers vagus nerve electrical stimulators medically necessary durable medical equipment for focal seizures or Lennox-Gastaut syndrome in members who remain refractory to optimal anti-epileptic medications and/or surgical intervention, or who have debilitating side effects from anti-epileptic medications, and who have no history of a bilateral or left cervical vagotomy. Replacement or revision of a system is considered medically necessary when the original system met criteria, is no longer under warranty, and cannot be repaired. Integrated VNS for multiple sclerosis, psoriatic arthritis and rheumatoid arthritis, transcutaneous VNS for seizures and post-laminectomy syndrome, VNS for prevention of chronic migraine, and VNS for all other listed indications (such as depression, obesity and tinnitus) are considered experimental, investigational or unproven.